Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
9 people get UCBJY.PK articles and Market Currents by email alert.
Get email alerts on UCBJY.PK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Rheumatoid Arthritis Slip-Up Unlikely To Affect Resurgent UCB SharesEP Vantage • Fri, Sep 28, 2012
To learn more about Seeking Alpha Pro, click here.
-
Rheumatoid Arthritis Slip-Up Unlikely To Affect Resurgent UCB SharesEP Vantage • Fri, Sep 28, 2012
There are no Transcripts on UCBJY.PK.
There are no News articles on UCBJY.PK.
UCBJY.PK vs. ETF Alternatives
Company Description
Currently, there's no company description for UCBJY.PK.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, December 28, 2011, 3:02 AM Immunomedics (IMMU) and UCB (UCBJF.PK) tweak their pact for developing and marketing epratuzumab, a drug for lupus, cancer and other diseases. The changes predominately concern marketing rights. UCB also gets a five-year warrant to buy 1M Immunomedics shares at $8 apiece; IMMU currently at $3.37. Comment! [Healthcare]
We currently have no instablog posts on this stock.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.